During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
The same applies to TB-500
8, 2025 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals
TB-500 is classified under WADA category S2 as a peptide hormone, growth factor, related substance and mimetic also banned in and out of competition
Powers Detoxification: Your liver, your body's main filter, absolutely depends on Glutathione to do its job